drtbear1967
Musclechemistry Board Certified Member
theguerillachemist
Bodybuilders know the compound SR9009, improperly called a SARM, for its potential to help burn fat. I’ve written my opinion about this in several posts, but this 2018 paper in Nature(the prestigious journal) caught my attention.
SR9009 is an REV-ERB agonist that affects certain nuclear hormone receptors that are essential to your body’s natural circadian rhythm. These researchers have shown IN VIVO(mice) that SR9009 has a lethal effect on cancer cells, but has no effect on normal healthy cells. This study shows SR9009 affects certain drivers for oncogenic activity such as HRAS, PIK3CA and BRAF, and triggers apoptosis, which is programmed cell death(in malignant tumor cells only). This study showed that SR9009 inhibited glioblastoma(brain cancer) growth in mice “without causing overt toxicity.” This is very exciting, although further research is needed. There are other papers that have shown REV-ERB agonists to be toxic to breast cancer in vitro(cells), as well as quite a few papers on a link between disruption of the circadian clock in mammals and cancer.
This is early stage research but hopefully the affecting the circadian rhythm can be an effective anti-cancer treatment. The main downfall for SR9009 is its low oral bioavailability, some papers cite as low as 2.9%. A topical or injectable version might be a more viable option.
Bodybuilders know the compound SR9009, improperly called a SARM, for its potential to help burn fat. I’ve written my opinion about this in several posts, but this 2018 paper in Nature(the prestigious journal) caught my attention.
SR9009 is an REV-ERB agonist that affects certain nuclear hormone receptors that are essential to your body’s natural circadian rhythm. These researchers have shown IN VIVO(mice) that SR9009 has a lethal effect on cancer cells, but has no effect on normal healthy cells. This study shows SR9009 affects certain drivers for oncogenic activity such as HRAS, PIK3CA and BRAF, and triggers apoptosis, which is programmed cell death(in malignant tumor cells only). This study showed that SR9009 inhibited glioblastoma(brain cancer) growth in mice “without causing overt toxicity.” This is very exciting, although further research is needed. There are other papers that have shown REV-ERB agonists to be toxic to breast cancer in vitro(cells), as well as quite a few papers on a link between disruption of the circadian clock in mammals and cancer.
This is early stage research but hopefully the affecting the circadian rhythm can be an effective anti-cancer treatment. The main downfall for SR9009 is its low oral bioavailability, some papers cite as low as 2.9%. A topical or injectable version might be a more viable option.
